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1. Introduction 
Acquired immunodeficiency syndrome (AIDS) is a disease caused by the infection of human 
immunodeficiency virus-1 (HIV-1) that primarily impairs immune function by reducing the 
CD4 T-lymphocyte count. More than two decades after the first clinical evidence of AIDS 
was reported, AIDS continues to be a major public health problem worldwide with millions 
of people infected and new infections rising in an alarming rate in third world countries 
especially in Asia and sub-Saharan Africa.(1, 2) AIDS has become one of the most 
devastating diseases that the scientific community has ever faced, struggling till today to 
come up with a therapeutic strategy that successfully controls the disease. AIDS is now the 
leading cause of death in sub-Saharan Africa, and is presently the fourth biggest killer 
worldwide. AIDS-related deaths totaled over 5 million by 2009 reaching a cumulative death 
toll of over 30 million since the beginning of the epidemic. More than 75 million people have 
been infected with HIV-1, and roughly 2.7 million new HIV-1 infections were diagnosed in 
2009(3) even though this rate has decreased from one decade ago. 
To date, there is no effective treatment and the number of individuals infected with HIV-1 is 
growing dramatically in the eastern part of the world. Considering its infection rate, it is 
imperative to devise newer strategies to control progression of the disease. Although newer 
approaches such as highly active antiretroviral therapy (HAART) have proven to be 
effective in prolonging life, other constraints associated with their use underscores the need 
for development of other effective therapies. Protease inhibitors appear to be successful at 
controlling the viral replication immediately following budding of immature virus particle, 
but the development of drug resistant viral mutants and toxicity after prolonged therapy 
contributes to their failure.(4) HAART has considerable toxicity and its inability to 
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effectively act on virus in secondary lymphoid tissue is a significant drawback. Vast 
majority of people with AIDS live in poorer countries. HAART is expensive and 
unreachable to low and middle-income countries.(5) Many of these places do not have 
access to HAART, or if they do, supply can be intermittent. The finding that infections with 
drug-resistant HIV-1 are increasing further underscores the need to develop inhibitors of 
HIV-1 that are effective, affordable and universally accessible. 
With the discovery of RNA interference (RNAi) phenomenon, that operates in mammalian 
cells and is highly effective in selective gene silencing, new, potent, small interfering RNA 
(siRNA) molecules have become available to add to control HIV-1. By analyzing the 
challenges of HIV-1 drug development, we review novel and multi-faceted therapies by 
simultaneously targeting multiple regions of HIV-1 so as to effectively cripple of the virus. 
The targets include essential cellular genes to avoid viral escape through mutations; 
multiple regions at various phases of the viral life cycle for a synergistic effect; and anti-
sense approach as well to avoid viral escape strategies of HIV-1 against RNAi. Current 
challenges facing the advancement of RNAi therapy are its safety and inefficient delivery in 
vivo. Self-complimentary recombinant adeno-associated viral (rAAV-sc) vectors can 
overcome shortcomings associated with RNAi-mediated gene silence therapy.(6) AAV 
vectors are safe and clinically proven. New generation vectors with mutant capsids 
circumvent pitfalls of ubiquitin-proteasome mediated degradation leading to high-efficiency 
transduction at low doses ideally suited to be part of a new arsenal for in vivo RNAi 
delivery to fight HIV-1.(7) Unlike present drugs in the clinical trial or R&D stage, the multi-
targeted AAV mediated RNAi approach not only kills the virus but also prevents the 
development of escape strategies and emergence of resistant viruses by simultaneous attack 
at multiple targets employing multiple technologies. 
2. Traditional AIDS therapies  
Anti-retroviral drugs such as nucleoside reverse transcriptase inhibitors and non-nucleoside 
inhibitors are first generation drugs successful in reducing the viral burden.(8-13) Although 
they prolong life in selected patients, these agents have significant side effects and generate 
drug resistant viral mutants. Protease inhibitors appear to be most effective at blocking HIV-
1 replication, substantially reducing AIDS-related hospital admissions and death rates.(14)  
Present-day therapy uses a combination of nucleoside analogues and protease inhibitors 
known as HAART.(15) HAART has been shown to be effective in controlling the spread of the 
virus by reducing the plasma viral load to undetectable levels and to some extent depleting the 
pool of virus in lymphoid tissues. In the past decade, HAART has become more effective with 
the introduction of several protease inhibitors, but the treatment is expensive and unavailable 
in poor countries.(5, 15) Approximately 30 million HIV-1 positive people of whom the vast 
majority live in low- and middle-income countries do not have access to proper treatment. 
This underscores the need for the development of inexpensive, yet effective drugs that can 
reach the majority of patients. Despite the apparent success of HAART therapy, the capacity of 
HIV-1 to establish latent infection of CD4+ T cells allows viral particles to persist in tissues. 
Some studies indicated that the therapy does not completely eliminate viral replication in 
secondary lymphoid tissues. HIV-1 was routinely isolated from lymphoid organs of patients 
even after years of therapy due to continued replication.(16) Moreover, the initiation of 
HAART even as early as days after the onset of AIDS symptoms, could not prevent the 
establishment of a pool of latently-infected T lymphocytes.(17)These observations clearly 
indicate that traditional combinatorial therapies with protease inhibitors and nucleoside 
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analogs for HIV-1, though effective in selected patients in prolonging life, unfortunately 
generate drug resistant viral mutants, unacceptable levels of drug toxicity, and are ineffective 
against virus in secondary lymphoid tissue. 
3. Newer approaches to therapy 
Introduction of molecules that are able to dominantly interfere with intracellular replication 
of HIV-1 is known as ‘‘intracellular immunization’’. Intracellular immunization by gene 
therapy strategies offers a promising alternative approach for controlling and managing 
HIV-1 disease. These include protein-based approaches such as trans-dominant strategies to 
inhibit HIV-1: toxins, zinc finger nucleases and single-chain antibodies.(18) Protein-based 
strategies have been the single largest area of anti-HIV-1 gene transfer trials in humans in 
the recent past.(19) Other RNA-based intracellular immunization approaches include the 
use of ribozymes and decoys. These second generation ribozymes are RNA molecules that 
cleave viral transcripts such as tat, rev, and gag at specific sequences targeting HIV-1 at 
critical stages, and have been shown to reduce HIV-1 levels in vitro.(20-22) RNA decoys are 
RNA homologues, such as TAR and RRE that bind viral proteins and compete with native 
ligands necessary for replication. They were also shown to inhibit HIV-1 in vitro.(20, 23, 24) 
In comparison with protein-based strategies, RNA-based approaches may have the 
advantage of not being immunogenic. Both viral or host cellular factors can be targeted, the 
latter potentially mitigating the possibility of escape mutants, but nevertheless, these trans-
dominant approaches had shown initial promise but fell short of practical utility in 
providing adequate protection. DNA-based vaccines have shown partial success.(23, 25, 26) 
Anti-sense molecules were shown by several groups to inhibit HIV-1 in vitro when targeted 
towards critical HIV-1 genes such as tat, rev, and integrase, but the need for large amounts 
for in vivo studies apart from the problems associated with stability contributed to their 
failure to enter the clinic.(27)   
4. RNA interference (RNAi): A natural way of gene silencing 
Diseases, for which a foreign gene can be identified as the cause, such as in the case of viral 
infections, are potentially treatable by blocking its expression that will cripple the causative 
agent. Over the last decade, small non-coding RNA molecules such as short interfering RNA 
(siRNA), micro RNA (miRNA) and piwi RNA (piRNA), collectively known as RNA 
interference (RNAi), emerged as critical regulators in mammalian gene expression and hold 
the promise of selectively inhibiting expression of disease-causing genes.(28, 29) RNAi is an 
evolutionarily conserved mechanism of gene inhibition or silencing first described in 
Caenorhabditis elegans and was shown to produce sequence-specific gene silencing.(30) In 
1999, it was recognized as the natural cellular process to destroy unwanted foreign genes 
such as those causing viral infections(31). In 2001, for the first time, the use of synthetic siRNA 
to silence genes in mammalian cells was demonstrated, and was referred to as ‘Biotech’s billion 
dollar break through.(32) In short, RNAi has the potential to revolutionize the treatment 
approach to various diseases. Over the years, it has become clear that RNAi is a highly 
conserved molecular mechanism used by eukaryotic organisms to control gene expression 
during development and to defend their genomes against invaders, such as transposons and 
RNA viruses. siRNAs are primarily exogenous in origin, derived directly from the virus or 
transposon. siRNAs are 21 to 23 double-stranded RNA molecules that recognize the cognate 
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mRNA with complementary sequence and cleave by naturally occurring cellular 
mechanisms.(31) In vivo silencing occurs after the formation of long double-stranded RNAs 
that are processed into short interfering RNAs (siRNAs) by an enzyme called Dicer, forming 
a ribonucleo-protein complex called RNA induced silencing complex (RISC). In the RISC, 
the anti-sense strand of the siRNA serves as a guide for the degradation of the homologous 
RNA target. In recent years, siRNA has emerged as a method of choice for specific and 
efficient gene silencing. 
Since discovery of their mechanism, chemically synthesized siRNA molecules are being 
used to target abnormally elevated genes in many diseases. Since siRNA is a natural 
biological mechanism against viruses, it can elicit specific intracellular antiviral resistance 
that may provide a therapeutic strategy against human viruses. siRNAs have been shown to 
inhibit viral replication or block gene expression in cell culture systems for several viruses. 
In one study, pre-treatment of cells siRNAs specific to the poliovirus genome promoted the 
clearance of the virus from most of the infected cells.(33) Shlomai et al observed significant 
reduction in hepatitis B virus (HBV) by siRNA-producing vectors.(34) A number of groups 
have demonstrated that siRNAs interfere with hepatitis C virus (HCV) gene expression and 
replication.(35-39) Over 90% of human cervical cancers are positive for human papilloma 
virus (HPV) and siRNA-mediated silencing of E6 and E7, the viral genes necessary for the 
HPV life cycle, completely inhibited them in mammalian cells.(40)  
5. Targeting HIV-1 with RNAi 
Since siRNA can elicit specific knockdown of transcripts and they have been successfully 
used against human viruses, this ancient defense mechanism can be recruited as a weapon 
in the fight against HIV-1. Several laboratories have shown that the introduction of siRNAs 
specific for HIV-1 transcripts has shown viral RNA degradation and inhibition of 
replication. (41-43) Stable and modified promoters for the expression of siRNA molecules 
have further shown to increase the potency of HIV in vitro.(44) The successful silencing of 
HIV-1 replication by several investigators through siRNA-mediated targeted knockdown of 
viral proteins made RNA interference a weapon of choice against HIV-1. (41, 45, 46) 
HIV-1 has a total of 15 proteins encoded by 9 genes.(47) Essentially, these can be grouped 
into four potential target sets for siRNA knockdown. The first potential target for gene 
silencing is the viral genomic RNA upon viral entry. Jacque et al demonstrated siRNA-
mediated destruction of incoming HIV-1(48), although other studies of RNAi inhibition of 
retroviral infection suggested that incoming genomic RNA may not be the best target for 
siRNAs.(49) Once viral DNA is integrated, the viral mRNA transcripts as well as the un-
spliced genomic RNA can be potential target. Early transcripts of HIV-1 such as rev, nef 
and tat are an important second group of targets for gene silencing with RNAi because 
they not only regulate the subsequent expression of the structural genes, gag, pol, and env 
but also the synthesis of full length viral genomic RNA. siRNA targeting the nef gene has 
been demonstrated to provide efficient silencing in a transient-transfection system.(50) 
There have been efficient demonstrations of silencing of the expression of various 
regulatory genes in a transient-transfection system.(44, 51, 52) siRNAs targeted to the TAR 
regulatory region and nef of the HIV-1 genome have also been shown to be effective at 
silencing the level of virus replication and inhibiting reverse transcription 
intermediates.(53, 54) After regulatory genes, structural genes also represent a potential 
target group.(55-57) It was found that inhibition was more significant when the siRNA 
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were present before the viral infection. This is because the vulnerability of genomic HIV 
RNA for RNAi-mediated knockdown is much greater immediately after viral entry into 
the cytoplasm due to the availability of target transcripts.  
A crucial finding was that a high degree of specificity of the RNAi for the sequence of its 
target was required. Even one base pair change dramatically lowers the potency of RNAi-
mediated inhibition.(58)This becomes important, given the high error rate of HIV-1 reverse 
transcriptase that leads to the emergence of RNAi escape mutants. The HIV-1 virus often 
becomes resistant to RNAi therapy as a result of the appearance of mutant variants. Because 
of these mutations, although siRNA directed against various HIV-1 genes shows initial 
success, the virus may soon escape inhibition within weeks. (44) Silencing evasion can also 
result from loss of target sequences within viral genomes, owing to the high viral mutation 
rates. In lymphocytes, for example, the effects of anti-HIV-1 siRNAs were progressively 
dampened by the emergence of viral quasi species that harbor mutations within the siRNA 
target sequence.(59) RNAi-mediated inhibition with single target has not yet been shown to 
protect cells against HIV-1 in long-term. RNAi could become a realistic therapeutic option, 
however, if used in a combined fashion while targeting multiple genes to prevent the 
emergence of mutant viruses. Simultaneous attacks by siRNA on various targets will 
minimize the escape of the resistant virus.  
6. Cellular targets of HIV for RNAi 
An essential cellular HIV receptor or co-receptor target may have more appeal than viral 
targets, which are prone to mutations. Cellular mRNAs that encode critical proteins involved 
in HIV-1 replication may circumvent pitfalls associated with viral escape mechanisms. 
Targeting cellular genes that are an essential part of the HIV-1 life cycle could therefore be 
advantageous. CD4 is the primary cellular receptor for HIV-1 entry on T lymphocytes. In 
addition to the CD4 primary receptor, the cellular chemokine receptors CCR5 and CXCR4, 
which function as co-receptors for HIV-1, have provided new therapeutic targets and a better 
understanding of the progression of viral infection. Several investigators targeted cellular 
proteins necessary for the HIV-1 life cycle by siRNAs and produced decreased levels of virus 
production.(60, 61)  Preliminary observations from various laboratories have demonstrated 
that siRNAs specific for CD4 receptor do indeed inhibit HIV-1 replication.(62, 63)  After 
transfection of cultured T cells with siRNA against the mRNA for CD4, HIV production, after 
exposure of the cells to the virus, decreased substantially. (64) CCR5, an HIV-1 co-receptor for 
the M-tropic HIV-1 variant, providing an attractive cellular target for siRNAs since 
homozygous deletions of CCR5 effectively confer protection from HIV-1 without any serious 
deleterious effects in immune function.(65) At least one group has taken advantage of this 
target for RNAi-mediated gene silencing, demonstrating that in vitro knockdown of CCR5 by 
siRNAs provided marked protection from HIV-1 infection.(63) 
Although suppression of the primary receptor CD4 may be restricted by its normal role in 
the immune system, CCR5 seems dispensable for normal life.(66) Unfortunately, not all 
HIV-1 strains require CCR5, and the inhibition of CCR5 may result in the selection of HIV-1 
variants that use CXCR4 as a co-receptor. It is critical to identify this particular aspect by 
studying strain variants.  
7. Escape strategies of HIV-1 from siRNA 
One of the hallmarks of RNAi is its sequence-specific knockdown of the target transcript, 
but unfortunately, it also presents a way out for HIV-1, since single nucleotide substitutions 
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in the target region can drastically decrease the efficiency of the knockdown. HIV-1 has a 
high mutation rate, and this is one of the reasons why RNAi gene silencing has not yet been 
shown to protect cells against HIV-1 in long-term virus replication assays although they 
were successful in the short term. For example, the effects of anti-HIV-1 siRNAs in 
lymphocytes were progressively dampened by the emergence of viral mutant genes tat and 
nef through nucleotide substitution or deletions within the siRNA target sequences.(44, 59) 
HIV-1 can also escape from RNAi-mediated inhibition through mutations that alter the local 
RNA secondary structure.(67) This emergence of escape mutants occurs even without 
necessarily changing the encoded protein after prolonged culturing. In order to circumvent 
the emergence of resistant viruses, targeting of conserved sequences and the simultaneous 
use of multiple siRNAs have been suggested. Further strategies to prevent this siRNA 
escape strategy by HIV-1 suggested the use of anti-sense for tat and nef genes. Unlike 
siRNA, the anti-sense approach is not a natural phenomenon occurring in the cells and no 
escape strategies have been developed by HIV-1. By the combination of gene knockout by 
two approaches, an effective and complete suppression of HIV-1 can be achieved.  
8. Multi-targeted knockdown of HIV-1 genes 
Although targeting a single HIV-1 sequence can result in strong inhibition of viral 
replication, it is likely followed by viral escape. Thus far, studies establishing the utility of 
siRNAs in suppressing HIV-1 infection failed in the long run because of the high mutation 
rate of HIV-1 replication. There are considerable challenges in achieving this long-term 
inhibition, preventing the transient success achieved from translating into clinical 
advantage. Therefore, approaches that not only target different stages of the viral life cycle 
but also simultaneously target specific sets of cellular genes that are needed for viral entry 
should be explored. In fact, it has been clearly demonstrated that the introduction of 
multiple siRNAs specific for HIV-1 could lead to viral RNA degradation and replication 
during different stages of the viral life cycle.(59) This multi-frontal RNAi-mediated attack on 
HIV-1 potentially inhibits the mutation escape mechanism. There have been several 
successful demonstrations of inhibition of HIV-1 replication using siRNA targeting distinct 
steps of the viral life cycle. HIV RNA in the post entry complex was successfully degraded 
abolishing the integration of proviral DNA when siRNAs targeted more than one 
region.(43) Dual-specific short hairpin siRNA constructs containing an intervening bridge, 
targeted against both receptors were demonstrated to successfully inhibit HIV-1 replication, 
thus demonstrating the practical utility of an siRNA multi-frontal attack on HIV-1.(60)  
It has been previously established that if the length of siRNA exceeds 30 bp, there is an 
induction of nonspecific antiviral interferon responses.(33) Contrary to this belief, it was 
shown recently that this phenomenon might not be applicable to all sequences. Chang et al. 
generated 38 bp siRNAs that can induce targeted gene silencing of more than one gene 
without nonspecific antiviral responses. This structural flexibility of gene silencing with 
siRNAs needs to be further explored in order to achieve complete inhibition of HIV-1 by 
targeting simultaneously several regions.(68) By targeting two separate regions to knockout 
transcription of the gene rev, the highest degree of inhibition of viral replication was 
achieved.(69) 
These newer drug designs had shown initial promise, but fell short of practical utility in 
providing adequate protection in every case. Since no effective therapy is currently available 
for prevention, new and innovative therapies are urgently needed to control, prevent and 
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eradicate HIV-1 disease. With this backdrop of HIV-1 drug development research, we 
propose to develop a cocktail of HIV-1 drug analogous to the current clinical use of 
combinations of antiviral drugs that target the reverse transcriptase and protease enzymes. 
These combinatorial approaches attacking multiple targets were designed essentially to 
prevent escape strategies observed by HIV-1 by various labs.  
Analogous to the current clinical practice of HAART therapy, RNAi approaches should also 
be administered in a combined fashion to prevent HIV-1 escape strategies.  
9. Limitations and hurdles of in vivo delivery of RNAi  
Although RNAi mediated inhibition through siRNAs to knockdown HIV-1 genes in the 
laboratory has been successful, transfection of these purchased siRNA from commercial 
sources is impractical and has little value for translational work. siRNA is highly labile and 
often requires exceptionally high levels to achieve gene silencing in vivo. Further, the gene-
silencing effect of siRNA is directly dependent on the number of molecules available in the 
cells, underscoring the need for development of plasmid vectors for the continuous 
synthesis of siRNA inside the cell. Current challenges facing the in vivo application of siRNA 
are the maintenance of duplex stability to avoid endonuclease degradation, need for 
improved delivery and the need to minimize immunological responses.(70) Though 
successful in vivo application of siRNA was demonstrated in liver through high-pressure tail 
vein injection in a murine model, its applicability to humans is limited.(71, 72) The quantity 
of siRNA necessary for efficient silencing is incompatible with scale-up to larger preclinical 
models.(73) Liposomal packaging(74) and chemical modification of the RNA and 
polyethylene glycol (PEG)(75) conjugated methods give stability to siRNA molecules, but 
still require large amounts of RNAi and are financially non-viable techniques. 
Hydrodynamic transfection of siRNA has been successful in targeting organs in mice, but 
this approach is not practical for clinical use. (76, 77) 
One way to address this problem is to construct a siRNA sequence for insertion in a vector 
for intracellular expression of siRNA. Here the siRNA cassette is driven by RNA polymerase 
III promoter such as U6 that express sense and antisense strands separated by short 
"hairpin" RNAs (shRNAs) that are cleaved by the dicer to produce siRNA. In some cases 
both the sense and anti-sense siRNA strands are transcribed separately, which then 
hybridize in vivo to make the siRNA. Expression from a DNA plasmid or a viral vector such 
as shRNA enhances stability and safe delivery of siRNA apart from providing continuous 
production in vivo. It has been demonstrated that the transfection of human cells with 
plasmid encoding shRNA against HIV-1 rev drastically inhibited viral replication over a 
period of several days. Further, the highest degree of inhibition of viral replication was 
achieved by simultaneously targeting two distinct sites within rev.(51, 69) 
Selection of highly accessible targets within the HIV-1 RNA genome should be determined 
first with antisense DNA oligonucleotide arrays before designing shRNA.(78, 79) There is 
recent evidence that the efficacy of siRNAs is similarly influenced by secondary structure in 
the target transcript.(80). These selection criteria should be used in the design of the siRNA 
molecule in order to get optimal inhibition.  
10. Efficient delivery and expression of shRNA by viral vectors 
One of the important limitations of siRNA-mediated drug delivery is the vehicle to carry the 
inhibitory molecules to the target cells. Viral vectors are generally more efficient vehicles for 
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shRNA in vivo than nonviral vectors.(81) Adenovirus, retro- or lentivirus, and AAV have 
been successfully used for this purpose. Retroviral/lentiviral vectors can potentially 
generate insertional mutagenesis, while adenoviral vectors trigger unacceptable levels of 
immune responses with concerns of safety.(82) shRNA can be packaged as recombinant 
viral vectors for better delivery in the whole organism. Retroviral vectors are successfully 
used for shRNA delivery, derived from moloney murine leukemia virus (MMLV). Lentiviral 
vectors are derived from HIV itself and can infect all the cells without the need for receptor 
interaction. Studies with lentiviral vectors silencing CCR5 have been performed but showed 
that the down regulating effect of CCR5 alone was insufficient. However, combinatorial 
constructs targeted to both CXCR4 and CCR5 and have shown better efficacy.(61) 
Retroviral/lentiviral vectors randomly integrate into the genome, generate insertional 
mutagenesis, and are derived from pathogenic viruses.  
Dual-specific short hairpin siRNA constructs containing an intervening spacer, targeting 
receptor and co-receptor, demonstrated the practical utility of shRNA constructs 
synthesized as a single transcript. Since the shRNA design will permit tandem assembly of 
multiple motifs, it is now possible to introduce promising multivalent siRNA constructs into 
viral vectors for in vivo gene therapeutic applications. Based on this rationale, recent work 
with synthetic siRNAs demonstrated that down regulating either CXCR4 or CCR5 will 
protect cells from X4 or R5 HIV-1 strains, respectively, at the level of viral entry.(83) As 
mentioned earlier, CCR5 is a co-receptor, necessary for cellular entry by HIV-1 (R5 tropic 
viral strain), but is dispensable for normal human physiology. Owing to its crucial role in 
HIV-1 infection, the CCR5 co-receptor has been the subject of many therapeutic approaches, 
including RNAi-mediated gene silence therapy. siRNA targeting was shown to be effective; 
however, complete knockdown remained an elusive goal. In one study, transgenic 
macrophages expressing high levels of CCR5 were used for testing the efficacy of lentiviral 
vectors carrying CCR5 shRNA. Lentiviral delivery of longer (28-mer) shRNA were shown to 
be very effective in gene knockdown.(84) Thus, anti-CCR5 shRNA viral delivery is a 
promising candidate for clinical application. 
We have tested retroviral vectors for gene therapy(85, 86); however, retroviral-mediated 
gene therapy is limited by a variety of practical and theoretical concerns, such as the 
immunogenicity of viral capsid proteins and insertional mutagenesis, which limit their 
utility for clinical purposes.(87)  
Adenoviral vectors have also been successfully used for the delivery of shRNA(88) but they 
are well known to trigger unacceptable levels of immune responsiveness due to their large 
size and thereby limit  repeat administration. Stability and efficiency is not the concern with 
viral vectors, but safety is a primary concern.  
11. Recombinant Adeno-Associated Virus (rAAV) – Ideal RNAi gene silence 
therapy vectors  
AAV belongs to the parvovirus family and is the only viral vector not known to be 
associated with any human disease(89) and the smallest vector suitable for RNAi-mediated 
gene silencing. Due to the safety(90), efficacy and potency provided by rAAV vectors, they 
make better alternative  to the more commonly-used retroviral, lentiviral and adenovirus 
based vectors for gene therapy. rAAV vectors are easy to propagate and have many 
characteristics that make them a better choice for somatic gene therapy with RNAi-mediated 
gene silencing.(91, 92) rAAV vectors have long been established to transduce a wide variety 
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of tissues.(93-95) First generation rAAV vectors were single stranded, but the development 
of self-complimentary (double stranded) rAAV vectors helped to avoid delay in trans-gene 
expression.(96) Multiple administration of the rAAV vectors is possible to overcome 
neutralization by the antibody produced following the initial administration due to the 
availability of multiple serotypes with significantly higher trans-gene expression levels than 
that of prototype single stranded-vectors.(97) rAAV-based vectors have the potential for 
stable long-term trans-gene expression. rAAV is naturally gutless vector, which do not 
express any viral genes or cause a cytotoxic cellular immune response in the host. 
Furthermore, rAAV vectors show only a modest frequency of integration into host genome, 
thus avoiding insertional mutagenesis.(89) Overall, rAAV vectors fulfill the requirements for 
an ideal in vivo RNAi delivery vehicle.  
12. Capsid mutant rAAV for enhanced transduction  
One of the shortcomings of the traditional rAAV vectorology is low transduction 
efficiency, which requires large doses of vectors to achieve the desired effect. This is due 
to the phosphorylation of AAV capsids at tyrosine residues in the cell, which leads to a 
ubiquitin-proteasome-mediated destruction of the majority of rAAV particles and a 
decrease in transduction efficiency.(98) Gene therapy with these traditional rAAV vectors 
necessitates the delivery of undesirably high doses of the virus in order to achieve 
therapeutic benefit.(99) Recent advances have lead to the generation of rAAV vectors with 
mutant capsids protecting them from ubiquitin-proteasome-mediated degradation in the 
cytosol, eventually leading to an increase in DNA transduction efficiency.(7) We acquired 
these next generation rAAV vectors from Dr. Srivastava’s laboratory consisting of a 
variant of rAAV-2/8 with a mutated capsid making the vector resistant to degradation in 
the cytosol.(7) By using triple-capsid mutant, pACG2-3M (Y444F, Y500F & Y730F)(7), 
along with the self-complimentary rAAV vector, we achieved a significant enhancement 
in  rAAV2-sc green fluorescent protein (GFP) mediated transduction (Fig-1). With pseudo-
typed rAAV vectors and capsid mutations, even greater in vivo transduction efficiency has 
been demonstrated.(7)  
 
 
Fig. 1. HEK-293 cells transduced with various preparations of rAAV-GFP showing 
transduction efficiency based on green fluorescence intensity. A. Wild type rAAV-GFP; B. 
rAAV double stranded-GFP; C. rAAV-Capsid mutant. 
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13. rAAV vectors for siRNA delivery in vivo as short hairpin RNA (shRNA) 
An ideal vector system for RNAi expression should be efficient and allow stable expression 
of the shRNA cassette without causing insertional mutagenesis or undesired immune 
responses. AAV is a small virus of 4.7 kb and relatively simple in its organization, 
comprising only two genes Rep and Cap. AAV vectors are extremely efficient tools for gene 
delivery in vitro and in vivo, as demonstrated by a number of laboratories. rAAV vectors 
have been shown to efficiently transduce hematopoietic cells.(100-102) Moreover, rAAV 
only retain inverted terminal repeats but do not express any viral genes and thus are gutless 
by design and definition more over it has not been associated with any human pathogenic, 
making it the vector of choice for human gene therapy. Because of their efficient 
transcription and inability to recombine with HIV-1, rAAV vectors represent a promising 
form of anti-retroviral gene therapy.(100) 
One of the first studies using rAAV vector to deliver shRNA by Tomar et al. provided initial 
proof of principle that rAAV vector particles can be engineered to express shRNA.(88) They 
showed efficient knockdown of p53 and caspase 8 proteins. Subsequent studies by several 
investigators further demonstrated the usefulness of the rAAV vectors to express the shRNA 
cassette.(103-106) rAAV vectors have also been successfully used for a variety of gene silence 
experiments.(103-105) Use of rAAV vector encoding an anti-sense RNA against HIV-1 has 
been well documented by various labs.(23, 27, 100, 107) We studied the effect of anti-sense p53 
gene transduction in a multiple myeloma cell line, ARH77, using AAV vector, where we 
delivered p53 cDNA in an anti-sense orientation.(108) In vivo studies in mice showed 
persistent knockdown of the target tyrosine hydroxylase in a Parkinson’s disease model. They 
further demonstrated that reduction in the target elicited behavioral defects in the treated mice 
and created a phenotype reminiscent of rodent models of Parkinson’s disease.  
rAAV-mediated transduction is very efficient, particularly when compared with passive 
entry of simple siRNA or plasmid DNA.(109-111) rAAV siRNA delivery has been recently 
tested by several groups  and shown to be highly efficient. Specific and efficient inhibition of 
HIV-1 replication was demonstrated in cultures.(91, 112) Together, this underscores the 
great promise of pseudo-typing shRNA-expressing AAV vectors to achieve targeted and 
controlled siRNA induction in vivo. Although the targeting of a single HIV-1 sequence can 
result in strong inhibition of viral replication, it is likely to be followed by viral escape. In 
fact, in most in vitro tests, siRNA did not stand the test of long-term protection against HIV-
1. To overcome this escape strategy by HIV-1, we have a multi-pronged attack on HIV-1. 
First, HIV-1 is targeted at multiple genes for inhibition. Second, HIV-1 entry is inhibited by 
targeting siRNA to its cellular receptor CCR5 that is resistant to mutation. Third, we are 
introducing an anti-sense approach to knockdown HIV-1 tat, shown to be responsible for 
siRNA escape. Synthetic bi-specific or combinatorial constructs targeting both CXCR4 and 
CCR5 receptors have shown to confer resistance to HIV-1 infection much stronger than that 
conferred by targeting each one alone, giving a clear indication that multiple targeting is 
better than a single target.(22, 43, 61, 113)  
14. Conclusion 
Gene silencing therapy has the potential to inhibit HIV-1 replication and increase patient 
quality of life as an additional therapeutic class, and may serve as an adjuvant to current 
HAART treatment. This review gives a brief introduction regarding the emergence of RNAi, 
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the hurdles to overcome to proceed to the next stage, and possible solutions. Although 
RNAi molecules can be introduced into cells as double stranded or expressed from a 
plasmid to inhibit abnormally elevated genes, transfection of these purchased molecules 
from commercial sources is impractical and has little value for translational work. The main 
difficulty thus far in extending the power of RNA interference (RNAi) to clinical practice has 
been the development of safe vectors coding for shRNAs to achieve persistent knockdown 
in vivo. rAAV vectors are different from other vectors, since the only gene expressed from 
recombinant vector is the trans-gene itself, naturally gutless by design and thus avoiding 
any cytotoxic cellular immune responses in the host. Furthermore, rAAV vectors show only 
a modest frequency of integration into the host genome, thus avoiding insertional 
mutagenesis, which has been a stumbling block for the clinical use of retroviral or lentiviral 
vectors. Development of self-complimentary (also known as double stranded) vectors to 
avoid delay in trans-gene expression(96, 114) and packaging with capsid mutants(115) to 
increase transduction efficiency has further contributed to rAAV vectorology. Recent 
advances in our understanding of RNAi make rAAV an especially attractive candidate for 
anti-HIV-1 gene therapy, and rAAV-based RNAi approaches can be combined with other 
therapeutic modalities to make a combinatorial therapy akin to HAART. 
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